|
(PQ5) Mitochondria in Leukemic Stem Cell Disease Progression
|
5R01CA205975-03
|
$386,619
|
GHAFFARI, SAGHI
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
(PQ8) Genetically faithful murine models for studying disease progression in chronic lymphocytic leukemia
|
5R01CA216273-02
|
$740,321
|
WU, CATHERINE
|
DANA-FARBER CANCER INST
|
|
(PQC2) Localization as a determinant of cancer dormancy
|
5R01CA194596-04
|
$525,066
|
LIN, CHARLES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
A cohort study among workers exposed to benzene in China
|
ZIA CP010120 02060
|
$79,723
|
Rothman, Nat
|
DCEG (NCI)
|
|
A Drug Delivery Strategy for Targeted Therapy of Chronic Lymphocytic Leukemia
|
2R01CA174844-04
|
$575,010
|
RADER, CHRISTOPH
|
SCRIPPS FLORIDA
|
|
A Label-Free, Point-of-Care Platform to Diagnose Acute Promyelocytic Leukemia
|
5R01CA190843-04
|
$311,458
|
SOHN, LYDIA
|
UNIVERSITY OF CALIFORNIA BERKELEY
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-05
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
A novel genetic pathway for survival of B-lymphoblastic leukemia-initiating cells
|
1R21CA209298-01A1
|
$218,588
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
A novel glutaminase-free mammalian asparaginase with minimized immunogenicity to enable expanded use in cancer therapy
|
1R41CA228622-01
|
$298,305
|
NGUYEN, HIEN-ANH
|
ENZYME BY DESIGN, INC.
|
|
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia Treatment
|
5R00CA183914-05
|
$148,607
|
WAN, LIXIN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
A Novel Positron Emission Tomography Strategy for Early Detection and Treatment Monitoring of Graft-versus-host Disease
|
5R01CA201719-03
|
$361,510
|
GAMBHIR, SANJIV
|
STANFORD UNIVERSITY
|
|
A Paradigm Shift in Chronic Lymphocytic Leukemia: Defining the Role of Hematopoietic Stem Cells in Leukemogenesis
|
1F30CA225070-01A1
|
$38,725
|
HU, EILEEN
|
OHIO STATE UNIVERSITY
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
3R44CA221513-02S1
|
$4,319
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A phase IIA trial for the safety and tolerability of CD24Fc in prophylaxis of graft vs host disease.
|
5R44CA221513-02
|
$982,509
|
DEVENPORT, MARTIN
|
ONCOIMMUNE, INC.
|
|
A rapid spontaneous murine model of CN-AML
|
3R01CA196658-03S1
|
$219,775
|
GRIMES, H
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A rapid spontaneous murine model of CN-AML
|
5R01CA196658-03
|
$567,086
|
GRIMES, H
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
A Role for KSHV in the Pathogenesis of Malignancies
|
ZIA SC 010356
|
$305,473
|
Tosato, Giovanna
|
CCR (NCI)
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196 03152
|
$477,453
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
AARP prospective study of diet and cancer
|
ZIA CP010196 03152
|
$477,453
|
Sinha, Rashmi
|
DCEG (NCI)
|
|
Aberrant signaling in acute myeloid leukemia
|
3R01CA204396-03S1
|
$231,795
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Aberrant signaling in acute myeloid leukemia
|
5R01CA204396-03
|
$459,674
|
KENTSIS, ALEX
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S1
|
$244,519
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S2
|
$55,717
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
3P30CA016520-42S3
|
$65,235
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center Support Grant
|
5P30CA016520-42
|
$7,716,753
|
VONDERHEIDE, ROBERT
|
UNIVERSITY OF PENNSYLVANIA
|
|
Activation of Proto-Oncogenes by Chromosomal Translocation
|
ZIA SC 010378
|
$374,676
|
Aplan, Peter
|
CCR (NCI)
|
|
Adipocytes are Important Players in the Acute Lymphoblastic Leukemia Microenvironment
|
5R01CA201444-03
|
$367,664
|
MITTELMAN, STEVEN
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Adoptive T cell Therapy for Pediatric Leukemia
|
ZIA BC 011565
|
$546,995
|
Fry, Terry
|
CCR (NCI)
|
|
Adult Leukemia Research Center
|
2P01CA018029-42A1
|
$3,990,001
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Advanced development and validation of targeted molecular counting methods for precise and ultrasensitive quantitation of low prevalence somatic mutations
|
3R33CA192980-03S2
|
$77,750
|
SALIPANTE, STEPHEN
|
UNIVERSITY OF WASHINGTON
|
|
Advanced Prodrug Treatment for CML
|
2R44CA224731-02
|
$1,016,040
|
WERNER, MILTON
|
INHIBIKASE THERAPEUTICS
|
|
Advancing biological and clinical applications of genomic Minimal Residual Disease detection in AML
|
1R01CA217954-01A1
|
$429,758
|
MALEK, SAMI
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
Aging-associated alterations in adaptive landscapes and the evolution of leukemia
|
3R01CA180175-05S1
|
$50,001
|
DEGREGORI, JAMES
|
UNIVERSITY OF COLORADO DENVER
|
|
Agricultural Cohort Consortium
|
ZIA CP010119 10537
|
$45,135
|
Beane Freeman, Laura
|
DCEG (NCI)
|
|
Agricultural Health Study - Biomarkers of Exposures and Effects in Agriculture
|
ZIA CP010119 10527
|
$813,241
|
Hofmann, Jonathan
|
DCEG (NCI)
|
|
ALL immunobiology and the bone marrow niche
|
ZIA BC 011295
|
$234,427
|
Fry, Terry
|
CCR (NCI)
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S1
|
$3,249,644
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-05S2
|
$1,000,000
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-05
|
$8,073,787
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Allogeneic T cells Transduced with an Anti-CD19 Chimeric Antigen Receptor
|
ZIA BC 011415
|
$19,101
|
Kochenderfer, James
|
CCR (NCI)
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|